NEUSTAR
23.3.2021 10:02:05 CET | Business Wire | Press release
Threat data feeds can help organisations strengthen their cybersecurity posture, according to a new report from Ponemon Institute, the pre-eminent research centre dedicated to privacy, data protection and information security policy. Neustar Inc. , a global information services and technology company and leader in identity resolution, sponsored the independently conducted study on the state of threat feed effectiveness in the United States and the United Kingdom.
As cyberthreats proliferate, many organisations are using threat feeds with insights from domain name system (DNS) data to help IT security teams better understand threats and block malicious activity. A large majority (79%) of the more than 1,000 security professionals participating in the Ponemon study said threat data feeds were essential to their organisation’s ability to achieve a strong cybersecurity posture, and more than half (55%) rate the quality of their threat feeds’ ability to pinpoint cyberthreats as very high.
Study participants said threat data feeds offer a number of benefits: they add unique data to better inform security (71%), increase preventive blocking to ensure a better defence (63%), reduce the mean time to detect and remediate an attack (55%), and reduce the time spent researching false positives (51%).
However, more than half (56%) of respondents also said threat feeds deliver data that is often too voluminous and/or complex to provide timely and actionable intelligence.
Neustar’s UltraThreat Feeds service addresses these issues by drawing on proprietary data derived from the company’s expansive authoritative and recursive DNS services, DDoS mitigation solutions, OneID system and IP geolocation data. This service, which processes the data and outputs the observations and key insights, has been designed by Neustar’s renowned DNS experts, as well as leading academic researchers. UltraThreat Feeds data, provided as either near real-time threat data feeds or via API calls (JSON format), enable organisations to detect potential threats and identify and stop bad traffic, both inbound and outbound.
“Facing an increase in the volume, sophistication and diversity of threats, enterprises are investing significant resources into threat intelligence solutions to bolster their cyber defences,” said Michael Kaczmarek, senior vice president at Neustar. “Solutions that deliver real-time information on active threats, like Neustar’s UltraThreat Feeds service, can quickly deliver ROI across many layers of an organisation’s defence by improving the performance of network and application security tools – such as SIEMs, TIPs, Next Gen Firewalls, IPS/IDS, WAFs, and DNS Firewalls – which require threat data to effectively detect and block malicious actors.”
Each of the organisations surveyed by Ponemon faced an average of 28 cyberattacks in the past two years. On average, respondents said 38% of these cyberattacks were not stopped because security teams lacked timely and actionable data from their data feeds. Respondents also reported that half (50%) of all attacks can be stopped using timely and actionable intelligence from their threat feeds.
“The deep, rich threat data delivered by Neustar’s UltraThreat Feeds service empowers users to identify indicators of compromise or malicious activity in near real time and act accordingly to limit or even prevent attacks,” added Kaczmarek.
The Ponemon report is based on survey responses from 1,025 IT security practitioners (70% of whom were at or above the supervisory level) in the U.S. and the U.K. whose organisations use threat data in their cybersecurity programmes or infrastructure. The most-represented industry was financial services (18% of respondents), followed by industrial and manufacturing (12%), retail (11%), public sector (11%), and health and pharmaceuticals (9%). Just over half of the participants were from organisations with a global headcount of more than 5,000 employees. The surveys were carried out in November 2020.
To access the full report, go to https://www.home.neustar/resources/whitepapers/state-of-threat-feed-effectiveness .
For more information about Neustar’s UltraThreat Feeds, visit https://www.home.neustar/security-intelligence/ultrathreat-feeds . To learn more about Neustar’s full suite of security solutions, visit https://www.home.neustar/security-solutions .
-ENDS-
About Neustar
Neustar is an information services and technology company and a leader in identity resolution providing the data and technology that enable trusted connections between companies and people at the moments that matter most. Neustar offers industry-leading solutions in marketing, risk, communications and security that responsibly connect data on people, devices and locations, continuously corroborated through billions of transactions. Neustar serves more than 8,000 clients worldwide, including 60 of the Fortune 100. Learn how your company can benefit from the power of trusted connections here: https://www.home.neustar
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210323005066/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
